5UM.F Genertec Universal Medical Group Company Limited
- Market cap
- EUR 1.04B
- P/E
- 4.0x
- P/B
- 0.36x
- ROE
- 10.5%
- Dividend yield
- 7.81%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 5UM.F undervalued?
Graham numberThe Graham number of Genertec Universal Medical Group Company Limited cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genertec Universal Medical Group Company Limited fundamental analysis
No fundamental analysis for Genertec Universal Medical Group Company Limited yet.
Genertec Universal Medical Group Company Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited, together with its subsidiaries, provides financing, advisory, and medical services in the Mainland China. It operates through two segments, Finance Business and Healthcare Business. The Finance Business segment offers direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services. Its Healthcare Business segment includes medical and healthcare services; hospital operations; import, export, and …
Full company profileGenertec Universal Medical Group Company Limited financial statements
Genertec Universal Medical Group Company Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.70B | 3.42B | 4.30B | 6.82B | 8.52B | 9.91B | 11.9B | 13.7B | 13.7B | 14.9B |
| Gross Profit | 1.73B | 2.17B | 2.59B | 3.18B | 3.55B | 4.20B | 4.49B | 4.57B | 4.59B | 5.03B |
| Operating Income | 1.19B | 1.56B | 2.00B | 2.42B | 2.69B | 3.21B | 3.35B | 3.23B | 3.09B | 3.26B |
| EBITDA | - | 1.60B | 1.89B | 2.36B | 2.67B | 3.04B | 3.18B | 3.41B | 3.56B | 3.88B |
| Net Income | 872M | 1.15B | 1.35B | 1.59B | 1.75B | 1.95B | 1.96B | 2.11B | 2.10B | 2.21B |
| EPS | - | 0.67 | 0.79 | 0.93 | 1.02 | 1.03 | 1.04 | 1.12 | 1.11 | 1.10 |
| Balance Sheet | ||||||||||
| Total Assets | 29.0B | 37.7B | 47.3B | 57.9B | 61.5B | 69.9B | 76.9B | 80.3B | 86.0B | 84.3B |
| Total Liabilities | 22.4B | 30.3B | 37.0B | 44.4B | 46.5B | 52.3B | 57.2B | 60.0B | 63.2B | 59.3B |
| Shareholders' Equity | 6.57B | 7.47B | 10.0B | 11.1B | 12.4B | 14.8B | 15.6B | 17.4B | 18.9B | 20.9B |
| Cash & Short-term Investments | 1.27B | 1.75B | 2.17B | 3.39B | 2.04B | 2.34B | 3.46B | 3.54B | 2.38B | 2.11B |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.38B | -5.07B | -5.73B | -1.82B | -972M | -1.40B | 2.06B | 4.99B | 1.14B | 5.78B |
| Capital Expenditure | 20.2M | 18.9M | 17.6M | 208M | 401M | 385M | 608M | 897M | 1.26B | 989M |
| Free Cash Flow | - | -5.09B | -5.75B | -2.03B | -1.37B | -1.79B | 1.45B | 4.10B | -117M | 4.79B |
| Ratios | ||||||||||
| ROE | 13.3% | 15.4% | 13.5% | 14.3% | 14.1% | 13.2% | 12.5% | 12.2% | 11.2% | 10.5% |
| ROA | 3.0% | 3.0% | 2.9% | 2.7% | 2.8% | 2.8% | 2.6% | 2.6% | 2.4% | 2.6% |
| Net Profit Margin | 32.3% | 33.6% | 31.5% | 23.3% | 20.5% | 19.6% | 16.5% | 15.5% | 15.4% | 14.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genertec Universal Medical Group Company Limited dividends
- Dividend yield
- 7.81%
- Forward dividend
- 0.04 EUR
- Payout ratio
- 27.9%
- Ex-dividend date
- Jun 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 615M | 0.31 | 27.9% |
| 2024 | CNY 615M | 0.33 | 29.2% |
| 2023 | CNY 592M | 0.31 | 28.1% |
| 2022 | CNY 580M | 0.31 | 29.6% |
| 2021 | CNY 483M | 0.26 | 24.8% |
| 2020 | CNY 454M | 0.26 | 26.0% |
| 2019 | EUR 407M | 0.24 | 25.6% |
| 2018 | EUR 337M | 0.20 | 24.9% |
| 2017 | EUR 254M | 0.15 | 22.2% |
| 2016 | EUR 188M | - | 21.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Genertec Universal Medical Group Company Limited
- Insiders 38.05%
- Institutions 29.04%
- Public & others 32.92%
- Shares outstanding 2.01B
- Free float 1.30B
Genertec Universal Medical Group Company Limited company profile
- Company name
- Genertec Universal Medical Group Company Limited
- Ticker
- 5UM.F
- ISIN
- HK0000255361
- Exchange
- Frankfurt Exchange
- Sector
- Financial Services
- Industry
- Consumer Finance
- Employees
- 23,266
- Fiscal year end
- December
- Address
- No. 90, Side Road of West Third Ring Middle Road, Beijing, China
- Phone
- 86 10 6899 1455
- Website
- umcare.cn
About Genertec Universal Medical Group Company Limited
Genertec Universal Medical Group Company Limited, together with its subsidiaries, provides financing, advisory, and medical services in the Mainland China. It operates through two segments, Finance Business and Healthcare Business. The Finance Business segment offers direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services. Its Healthcare Business segment includes medical and healthcare services; hospital operations; import, export, and trading of medical-related goods; equipment life cycle management; medical digitalization services; and intelligent medical health and elder care. The company also provides medical and professional technology, financing, hospital management, medical consulting, sale of medical related goods, medical, software development, and elderly care services. It serves patients, hospitals, medical equipment suppliers, and other public institutions. The company was formerly known as Universal Medical Financial & Technical Advisory Services Company Limited and changed its name to Genertec Universal Medical Group Company Limited in July 2018. The company was founded in 1984 and is headquartered in Beijing, China.
Genertec Universal Medical Group Company Limited management
6- Mr. Shisu ChenExecutive Chairman · born 1972
- Ms. Lin WangExecutive Director · born 1974
- Mr. Qi XiaCEO & Executive Director · born 1976
- Ms. Shinan WangChief Accounting Officer & Chief Compliance Officer · born 1983
- Mr. Feng QingmingChief Medical Officer
- Ms. Wai Kam Ng A.C.I.S., A.C.S.Company Secretary